X4 PHARMACEUTICALS, INC Asset Acquisition Consideration Transferred Other Assets
X4 PHARMACEUTICALS, INC (XFOR) reported Asset Acquisition Consideration Transferred Other Assets of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AssetAcquisitionConsiderationTransferredOtherAssets · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for the quarter ending 2026-06-30 was $5.00M.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for the quarter ending 2025-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for the quarter ending 2025-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for fiscal 2025 was $3.00M, a 57.14% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for fiscal 2024 was $7.00M.
- X4 PHARMACEUTICALS, INC asset acquisition consideration transferred other assets for fiscal 2023 was $0.00.
| Period end | Asset Acquisition Consideration Transferred Other Assets 3 month | Asset Acquisition Consideration Transferred Other Assets 6 month | Asset Acquisition Consideration Transferred Other Assets 9 month | Asset Acquisition Consideration Transferred Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.00M 10-Q · filed 2026-08-06 | $5.00M derived: sum of 3 quarters · filed 2026-08-06 | $5.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $3.00M 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $3.00M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.00M 10-Q · filed 2026-08-06 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | $3.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.00M 10-Q · filed 2026-05-06 | $3.00M derived: sum of 2 quarters · filed 2026-05-06 | $3.00M derived: sum of 3 quarters · filed 2026-05-06 | $10.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $7.00M derived: sum of 3 quarters · filed 2026-03-17 | $7.00M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.00M derived: sum of 2 quarters · filed 2025-11-05 | $7.00M 10-Q · filed 2025-11-05 | $7.00M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $7.00M 10-Q · filed 2025-08-08 | $7.00M derived: sum of 3 quarters · filed 2026-03-17 | $7.00M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |